secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001628280-24-039948
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO
--------------------------------------------------------------------------------

- Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.
- Upfront payment $100M plus $75M escrowed milestone; up to $323M dev/reg milestones, $1.488B sales milestones, and low single to low double-digit tiered royalties.
- Jason O'Byrne appointed EVP and CFO effective Oct 2, 2024; base salary $530K, target bonus 45%, sign-on $450K, equity awards of 150K options and 75K RSUs.
- Clinical assets: SAR446309 (HER2) in Phase 1, SAR446329 (PSMA) in Phase 1, SAR446368 (EGFR) IND active, Phase 1 start expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024039948/0001628280-24-039948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024039948/vir-20240906.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-039948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer